Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abstral REMS Assessment To Look At Impact On Patient Access, Health Care System

Executive Summary

The extensive REMS assessment for ProStrakan's Abstral details the data collection burden sponsors face as they institute restricted distribution programs and FDA asks more questions about the burden placed on the health care system as well as the effects on patient access to medications.
Advertisement

Related Content

Abstral REMS Sets Stage For Risk Reduction Plans For Similar Fentanyls
Abstral REMS Sets Stage For Risk Reduction Plans For Similar Fentanyls
Abstral REMS Sets Stage For Risk Reduction Plans For Similar Fentanyls

Topics

Advertisement
UsernamePublicRestriction

Register

PS053021

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel